Shares of Illumina (ILMN) Sees Large Inflow of Net Money Flow

Illumina (ILMN) : $1.55 million worth of transactions were on upticks in Illumina (ILMN), compared to $0.62 million on downticks. The ratio between the two was 2.5, whereas, the net money flow stood at a healthy $0.93 million on Mondays session. The consistent buying on upticks in the stock accounted for $0.1million worth of trades. The total money flow into the stock stood at $0.1 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.12%. The stock was trading at $148.53, with a drop of $0.18 over the previous days close. The stock recorded 5.15% for the week.


Illumina Inc. has dropped 16.03% during the last 3-month period . Year-to-Date the stock performance stands at -22.08%. Shares of Illumina Inc. rose by 7.11% in the last five trading days and 9.7% for the last 4 weeks. In a related news,The director of Illumina Inc, Bowman A Blaine sold 5,000 shares at $147.54 on July 14, 2016. The Insider selling transaction had a total value worth of $737,700. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Illumina (NASDAQ:ILMN): stock turned positive on Monday. Though the stock opened at $148.72, the bulls momentum made the stock top out at $150.2992 level for the day. The stock recorded a low of $148.08 and closed the trading day at $149.57, in the green by 0.58%. The total traded volume for the day was 711,788. The stock had closed at $148.71 in the previous days trading.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.